<DOC>
	<DOCNO>NCT02007863</DOCNO>
	<brief_summary>Unrelated Cord Blood ( UCB ) transplant child viable stem cell transplant modality patient leukemia myelodysplasia . UCB consider `` Standard Of Care '' case suitable live bone marrow donor available . The survival UCB similar Matched Unrelated Marrow Transplant . This study consider `` Research '' since UCB license product require investigational new drug ( IND ) . THERE ARE NO SPECIFIC RESEARCH QUESTIONS IN THIS PROTOCOL . This protocol merely provide UCB stem cell treatment modality pediatric patient may require condition regimen excludes Total Body Irradiation .</brief_summary>
	<brief_title>Umbilical Cord Blood ( UCB ) Transplantation Pediatric Patients With High Risk Leukemia Myelodysplasia</brief_title>
	<detailed_description>The preparative regimen consist : - Fludarabine : 25 mg/m2/day IV x 5 dos Days -13 , -9 - Busulfan 1mg/kg IV every 6 hr x 16 dos Days -8 -5 - Melphalan 45 mg/m2/day IV x 3 dos day -4 -2 - ATGAM 30mg/kg/day x 3 dos Days -3 -1 - Day 0 day UCB Transplant - The graft-versus-host-disease ( GVHD ) prophylaxis Cyclosporin A maintain level 200-400 beginning Day -3 , 200-400 . Solumedrol 1mg/kg/day Day 1 D+4 , solumedrol 2mg/kg/day Day +19 till absolute neutrophil count ( ANC ) reach 500/mm2 , taper 0.2 mg/kg/week .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients must 21 year age Patients receive total body irradiation ( TBI ) : Young age &lt; 2 year diagnosis leukemia result age &lt; 4 year transplantation ( due risk severe growth retardation brain damage ) . Inability tolerate TBI prior radiation organ toxicity . Refractory/multiply relapse leukemia , traditional TBI/cyclophosphamide regimen would unlikely lead successful outcome . Patients must partially human leukocyte antigen ( HLA ) match UCB unit . Unit must HLAmatched minimally 4 6 HLAA B ( intermediate resolution molecular typing ) DRB1 ( high resolution molecular typing ) locus patient . The unit must deliver precryopreserved nucleated cell dose least 2.5 x 10^7 per kilogram . Acute myelogenous leukemia ( AML ) follow stage : High risk first complete remission ( CR1 ) , define : Having precede myelodysplasia ( MDS ) High risk cytogenetics ( Highrisk cytogenetics : del ( 5q ) 5 , 7 , abn ( 3q ) , ( 6 ; 9 ) complex karyotype ( &gt; = 5 abnormality ) Requiring &gt; 2 cycle chemotherapy obtain CR ; Second great CR . First relapse &lt; 25 % blast bone marrow . Patients therapyrelated AML whose prior malignancy remission least 12 month . Acute lymphocytic leukemia ( ALL ) follow stage : High risk first remission , define : 1 . Ph+ ALL ; , 2 . Myeloid/lymphoid leukemia ( MLL ) rearrangement slow early response [ define M2 ( 525 % blast ) M3 ( &gt; 25 % blast bone marrow examination Day 14 induction therapy ) ] ; , 3 . Hypodiploidy ( &lt; 44 chromosome DNA index &lt; 0.81 ) ; , 4 . End induction M3 bone marrow ; , 5 . End induction M2 M23 Day 42 . High risk second remission , define : 1 . Bone marrow relapse &lt; 36 month induction ; , 2 . Tlineage relapse time ; , 3 . Very early isolated central nervous system ( CNS ) relapse ( 6 month diagnosis ) ; , 4 . Slow reinduction ( M23 Day 28 ) relapse time . Any third subsequent CR . Biphenotypic undifferentiated leukemia CR 1st relapse must &lt; 25 % blast bone marrow ( BM ) . MDS stage . Chronic myelogenous leukemia ( CML ) chronic accelerate phase . All patient evidence CNS leukemia must treat CNS CR eligible study . Patients ≥ 16 year old must Karnofsky score ≥ 70 % patient &lt; 16 year old must Lansky score ≥ 70 % . Signed informed consent . Patients adequate physical function measure : 1 . Cardiac : Left ventricular ejection fraction rest must &gt; 40 % , shorten fraction &gt; 26 % 2 . Hepatic : Bilirubin ≤ 2.5 mg/dL ; alanine transaminase ( ALT ) , aspartate transaminase ( AST ) Alkaline Phosphatase ≤ 5 x upper limit normal ( ULN ) 3 . Renal : Serum creatinine within normal range age , serum creatinine outside normal range age , renal function ( creatinine clearance GFR ) &gt; 70 mL/min/1.73 m2 . 4 . Pulmonary : Diffusing capacity lung carbon monoxide ( DLCO ) , Forced expiratory volume 1 second ( FEV1 ) , Forced vital capacity ( FVC ) ( diffusion capacity ) &gt; 50 % predict ( correct hemoglobin ) ; unable perform pulmonary function test , O2 saturation &gt; 92 % room air . Pregnant ( Bpositive HCG ) breastfeeding . Evidence HIV infection HIV positive serology . Current uncontrolled bacterial , viral fungal infection ( currently take medication progression clinical symptom ) . Autologous transplant &lt; 6 month prior enrollment . Prior autologous transplant disease UCB transplant perform . Allogeneic hematopoietic stem cell transplant &lt; 6 month prior enrollment . Active malignancy one UCB transplant perform within 12 month enrollment Active CNS leukemia . Requirement supplemental oxygen . HLAmatched related donor able donate .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myelodysplasia</keyword>
	<keyword>Acute lymphocytic leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Acute myelogenous leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Pediatric</keyword>
</DOC>